However, treatment with 10 mM metformin did significantly reduce NSCLC cell HES1 expression (p = 0.011; Figure 2), suggesting HES1 may be involvemed in metformin’s anti-tumorigenic properties. Here, HES1 is linked to non-small cell lung carcinoma.